Form D · Other

PHARMATHENE, INC

Annapolis, MD · CIK 0001326190

Offering snapshot reported Nov 19, 2010 · SEC filing

Reported sold
$9.9M
Offering amount: $22.6M
Investors reported
22
Form D · investor count
Minimum accepted
$6K
Reported outside-investor minimum
First sale
Nov 3, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 19, 2010Initial$9,895,186No comparison22SEC filing
Aug 12, 2009Initial$19,295,802No comparison22SEC filing
Oct 27, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-150748
In connection with conversion of convertible notes issued under Regulation D. Remaining amount assumes conversion at maturity.

Source: Form D, filed Nov 19, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Christopher C. Camut Executive
James H. Cavanaugh Director
Francesca Cook Executive
Thomas R. Fuerst Executive
Joan Fusco Executive
John Gill Director
Jordan P. Karp Executive
Joel Mc Cleary Director
Wayne Morges Executive
John Pappajohn Director
Charles A. Reinhart Iii Executive
Eric I. Richman Executive
Valerie C. Riddle Executive
Jeffrey W. Runge Director
Mitchel Sayare Director
Derace L. Schaffer Director
Steven St. Peter Director
David P. Wright Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
One Park Place, Suite 450
Annapolis, MD, 21401